During a Case-Based Roundtable meeting, Lipson and participants talked about the complexity of choosing the right therapy for ...

The approval of durvalumab, based on data from the phase 3 ADRIATIC study, offers a new standard of care for patients with ...

The FDA has approved zenocutuzumab, making it the first and only approved targeted therapy for patients with NRG1+ NSCLC and ...

Francis P. Worden, MD, discusses how the effectiveness of lenvatinib in this real-world setting compares with results from ...

The FDA granted breakthrough therapy status to sacituzumab tirumotecan in EGFR-mutated advanced non–small cell lung cancer.

Sonodynamic therapy doubled the median overall survival to 15.7 months and tripled progression-free survival to 5.5 months in ...

Enrollment in cohort 5 of the phase 1/2 GOBLET study will resume after the Data Safety Monitoring Board’s safety review.

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the CEPHEUS trial results and impact on frontline treatment in ...

Targeted Oncology co-hosts Kristie L. Kahl and Andrew Svonavec highlight abstracts for community oncologists to look out for ...

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the results and potential impact from the phase 3 CEPHEUS trial.

TERN-701 showed promising early results, with significant molecular responses and a strong safety profile in heavily ...

Joe DePinto, MBA, discusses the complexity of the cell and gene therapy ecosystem and the need for collaboration with ...